2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Payload
  5. Maytansinoids Isoform

Maytansinoids

Maytansinoids are potent microtubule-targeted compounds that inhibit cell proliferation by arresting cells in mitotic prometaphase/metaphase[1]. Mechanistically, maytansine, DM1 metabolites, and antibody-maytansinoid conjugates suppress microtubule dynamic instability rather than requiring microtubule depolymerization at active concentrations[1][2]. This antimitotic mechanism supports their use as cytotoxic payloads in antibody-drug conjugates, where monoclonal antibodies deliver maytansinoids to antigen-expressing tumor cells[3]. In breast tumor cells, anti-EpCAM-DM1 conjugates required internalization and intracellular processing before inducing abnormal spindle organization and mitotic arrest[1]. In mouse xenograft models, T-DM1, SAR3419, and IMGN901 delivered active maytansinoid catabolites to tumor tissue, and linker chemistry affected plasma pharmacokinetics and catabolites in tumor and liver tissues[4]. Compared with colchicine-site agents, maytansinoids act at the vinblastine-maytansine tubulin-binding site, defining a mechanistic distinction among antimitotic tubulin ligands[5]. For research applications, DM1 and DM4 conjugates provide tools to study target-dependent cytotoxicity, linker-dependent ADME, microtubule dynamics, mitotic arrest, and ADC activity in tumor models[1][3][4].

Maytansinoids Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-19792
    Mertansine
    		99.80%
    Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC).
  • HY-15739
    Ansamitocin P-3
    		98.0%
    Ansamitocin P-3 (Antibiotic C 15003P3) is a microtubule inhibitor. Ansamitocin P-3 is a macrocyclic antitumor antibiotic.
  • HY-126663
    N-Me-L-Ala-maytansinol
    		99.89%
    N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate (ADC).
  • HY-130082
    DM4-SMe
    		99.99%
    DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC50 of 0.026 nM. DM4-SMe is a highly toxic metabolite that can be oxidized and detoxified by human liver microsomes.
  • HY-100128
    DM1-SMe
    		99.08%
    DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin.
  • HY-130080
    DM3
    DM3 (Maytansinoid DM3), a Maytansine (HY-13674) analog bearing disulfide or thiol groups, and is a tubulin inhibitor. DM3 a cytotoxic moiety of antibody-drug conjugates (ADCs).
  • HY-100504
    S-methyl DM1
    		99.57%
    S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a Kd of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects.
  • HY-100503
    Maytansinoid DM4
    Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC.
  • HY-130081
    DM3-SMe
    DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC50 of 0.0011 nM.